Actively Recruiting
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
Led by Karen-Lise Garm Spindler · Updated on 2024-08-14
350
Participants Needed
2
Research Sites
435 weeks
Total Duration
On this page
Sponsors
K
Karen-Lise Garm Spindler
Lead Sponsor
V
Vejle Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
A study investigating if analysis of circulating tumor DNA (ctDNA) can guide adjuvant treatment in patients with advanced colorectal cancer (CRC)
CONDITIONS
Official Title
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Radical intended treatment for metastatic spread from colorectal cancer by resection, radiofrequency ablation, stereotactic body radiation therapy, or other experimental local treatments (excluding cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy)
- No evidence of further disease based on pre-treatment work-up according to standard of care
- Age 18 years or older
- Eastern Cooperative Oncology Group performance status 0-2
- Clinically eligible for adjuvant triple combination chemotherapy as decided by investigator
- Adequate bone marrow, liver, and kidney function suitable for systemic chemotherapy (specified blood counts and liver enzyme limits, and kidney filtration rate at least 30 mL/min)
- Use of contraception for fertile women and male patients with fertile partners (intrauterine device, vasectomy, or hormonal contraceptives acceptable)
- Provided written and verbal informed consent
You will not qualify if you...
- Radiological evidence of distant metastases on CT scans of chest, abdomen, and pelvis
- Incapacity, frailty, disability, or comorbidities making triple combination chemotherapy unsuitable
- Neuropathy grade higher than 1 according to NCI-CTCAE
- Other malignant tumors within 5 years except non-melanoma skin cancer or carcinoma in situ of the cervix
- Pregnant or breastfeeding women
- Intolerance or allergy to 5-FU, leucovorin, oxaliplatin, irinotecan, or capecitabine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Oncology, Aarhus University Hospital
Aarhus N, Denmark, 8200
Actively Recruiting
2
Department pf Oncology, Vejle Hospital
Vejle, Denmark, 7100
Actively Recruiting
Research Team
K
Karen-Lise G Spindler, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here